Following the integrated clinical strategy of cardiac-cerebral co-management and interventional prophylaxis against stroke, the company provides a full solution portfolio for atrial fibrillation, consisting of the C-Clip® Left Atrial Appendage (LAA) Closure System, Fidus® LAA Occluder, and surgical radiofrequency ablation systems.
C-Clip® is the world’s second domestically developed LAA closure system approved for the prevention of cardioembolic stroke in AF patients. The surgical radiofrequency ablation series for atrial fibrillation is the only domestically manufactured product of its kind and the third globally, breaking the long-standing market monopoly of U.S. imported products and enabling substantial substitution by domestic alternatives. Given China’s vast AF patient population and substantial room to raise standardized treatment rates, this business line bears strong unmet clinical demands and high commercialization potential.
Across all therapeutic segments, the company maintains a multi-stage pipeline: commercially available products, products under registration review, and early-stage R&D assets. To date, the company holds 11 NMPA medical device registration certificates, including four domestically exclusive alternative products, three original domestic innovations, and one globally unique device. It has also obtained 5 FDA clearances and CE marking certificates. Against the national backdrop of domestic alternatives to high-end cardiovascular implants, these credentials build a solid, differentiated competitive moat.
